Breitinger Ulrike, Ali Nourhan K M, Sticht Heinrich, Breitinger Hans-Georg
Department of Biochemistry, German University in Cairo, New Cairo, Egypt.
Division of Bioinformatics, Institute of Biochemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Front Microbiol. 2021 Jul 8;12:692423. doi: 10.3389/fmicb.2021.692423. eCollection 2021.
Severe acute respiratory syndrome coronavirus (SARS-CoV), an enveloped single-stranded positive-sense RNA virus, is a member of the genus , family Coronaviridae. The SARS-CoV envelope protein E is a small (∼8.4 kDa) channel-forming membrane protein whose sequence is highly conserved between SARS-CoV and SARS-CoV-2. As a viroporin, it is involved in various aspects of the virus life cycle including assembly, budding, envelope formation, virus release, and inflammasome activation. Here, SARS-CoV E protein was recombinantly expressed in HEK293 cells and channel activity and the effects of viroporin inhibitors studied using patch-clamp electrophysiology and a cell viability assay. We introduced a membrane-directing signal peptide to ensure transfer of recombinant E protein to the plasma membrane. E protein expression induced transmembrane currents that were blocked by various inhibitors. In an ion-reduced buffer system, currents were proton-dependent and blocked by viroporin inhibitors rimantadine and amantadine. I-V relationships of recombinant E protein were not pH-dependent in a classical buffer system with high extracellular Na and high intracellular K. E-protein mediated currents were inhibited by amantadine and rimantadine, as well as 5-(N,N-hexamethylene)amiloride (HMA). We tested a total of 10 flavonoids, finding inhibitory activity of varying potency. Epigallocatechin and quercetin were most effective, with IC values of 1.5 ± 0.1 and 3.7 ± 0.2 nM, respectively, similar to the potency of rimantadine (IC = 1.7 ± 0.6 nM). Patch-clamp results were independently verified using a modified cell viability assay for viroporin inhibitors. These results contribute to the development of novel antiviral drugs that suppress virus activity and proliferation.
严重急性呼吸综合征冠状病毒(SARS-CoV)是一种有包膜的单链正链RNA病毒,属于冠状病毒科冠状病毒属。SARS-CoV包膜蛋白E是一种小的(约8.4 kDa)形成通道的膜蛋白,其序列在SARS-CoV和SARS-CoV-2之间高度保守。作为一种病毒孔蛋白,它参与病毒生命周期的各个方面,包括组装、出芽、包膜形成、病毒释放和炎性小体激活。在此,SARS-CoV E蛋白在HEK293细胞中重组表达,并使用膜片钳电生理学和细胞活力测定法研究其通道活性和病毒孔蛋白抑制剂的作用。我们引入了一个膜导向信号肽,以确保重组E蛋白转移到质膜。E蛋白表达诱导的跨膜电流被各种抑制剂阻断。在离子减少的缓冲系统中,电流依赖于质子,并被病毒孔蛋白抑制剂金刚乙胺和金刚烷胺阻断。在具有高细胞外钠和高细胞内钾的经典缓冲系统中,重组E蛋白的电流-电压关系不依赖于pH。E蛋白介导的电流被金刚乙胺、金刚烷胺以及5-(N,N-六亚甲基)氨氯吡脒(HMA)抑制。我们总共测试了10种黄酮类化合物,发现它们具有不同程度的抑制活性。表没食子儿茶素和槲皮素最有效,IC值分别为1.5±0.1和3.7±0.2 nM,与金刚乙胺的效力(IC = 1.7±0.6 nM)相似。使用改良的病毒孔蛋白抑制剂细胞活力测定法独立验证了膜片钳结果。这些结果有助于开发抑制病毒活性和增殖的新型抗病毒药物。